GSK, As­traZeneca plan to har­ness AI pow­er for drug de­vel­op­ment from Nvidi­a's new, $50M-plus su­per­com­put­er now un­der con­struc­tion

Cal­i­for­nia-based tech com­pa­ny Nvidia is putting down £40 mil­lion ($51.7 mil­lion) to build one of the world’s most pow­er­ful su­per­com­put­ers — and As­traZeneca and GSK will be among the first to use it.

The ma­chine, named Cam­bridge-1, is part of Nvidia’s mas­ter plan to open a “cen­ter of ex­cel­lence” in the Eu­ro­pean tech hub. The com­put­er will pack more than 400 petaflops of AI per­for­mance, which could be used to stream­line drug dis­cov­ery, CEO Jensen Huang said. A petaflop mea­sures a com­put­er’s pro­cess­ing speed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.